Incyte (INCY)
(Delayed Data from NSDQ)
$64.14 USD
+1.12 (1.78%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $64.15 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Incyte (INCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$72.33 | $88.00 | $48.00 | 14.77% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Incyte comes to $72.33. The forecasts range from a low of $48.00 to a high of $88.00. The average price target represents an increase of 14.77% from the last closing price of $63.02.
Analyst Price Targets (18)
Broker Rating
Incyte currently has an average brokerage recommendation (ABR) of 2.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.24 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, nine are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/INCY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 11 | 11 | 12 | 12 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 2.24 | 2.24 | 2.24 | 2.14 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
8/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
7/30/2024 | Not Identified | Not Identified | Hold | Hold |
7/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | BMO Capital Markets | Evan Seigerman | Hold | Strong Sell |
5/1/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
5/1/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
2/14/2024 | JMP Securities | Reni Benjamin | Strong Buy | Hold |
12/4/2023 | Guggenheim Securities | Michael Schmidt | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.24 |
ABR (Last week) | 2.24 |
# of Recs in ABR | 21 |
Average Target Price | $72.33 |
LT Growth Rate | 18.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 1.35 |